Patent application number | Description | Published |
20090155289 | FURIN-CLEAVABLE PEPTIDE LINKERS FOR DRUG-LIGAND CONJUGATES - Disclosed are certain peptide linkers for conjugating drugs to ligands, and the resulting drug-linker-ligand molecules and compositions thereof. The conjugated molecules useful for the targeted delivery of drugs to the desired cells, and allow for the intracellular release of the drug in cases where the targeted antigen is internalized via the trans Golgi network and not the lysosomal pathway. | 06-18-2009 |
20090275587 | METHODS OF TREATING ISCHEMIC RELATED CONDITIONS - The present invention relates to methods of treating ischemia-related conditions by administering to a patient in need of such methods certain thiosemicarbazone compounds. Preferred embodiments of the present invention relates to methods of treating specific ischemia-related conditions, including but not limited to Alzheimer's disease, Parkinson's disease, Coronary artery bypass graft surgery, Global cerebral ischemia due to cardiac arrest, focal cerebral infarction, cerebral hemorrhage, hemorrhage infarction, hypertensive hemorrhage. hemorrhage due to rupture of intracranial vascular abnormalities, subarachnoid hemorrhage due to rupture of intracranial arterial aneurysms, hypertensive encephalopathy, carotid stenosis or occlusion leading to cerebral ischemia, cardiogenic thromboembolism, spinal stroke and spinal cord injury, diseases of cerebral blood vessels: e.g., atherosclerosis, vasculitis, Macular degeneration, myocardial infarction, cardiac ischemia and superaventicular tachyarrhytmia. | 11-05-2009 |
20090298097 | METHODS FOR THE DIAGNOSIS OF LUNG CANCER - The present invention is directed to new ways to diagnosis lung cancer, especially at an early clinical stage. In addition, prognosis and the monitoring of therapeutic agents or other treatments, for lung cancer patients, can be accomplished with the disclosed methods. The methods also find use in allowing the assessment by pre-clinical animal efficacy studies to screen for the useful of therapeutic agents for treating lung cancer. | 12-03-2009 |
20100093002 | Diagnosis and treatment of malignant neoplasms - The invention features a method of inhibiting tumor growth and/or tumor invasiveness in a mammal by administering to a mammal a compound (e.g., an antagonistic antibody) which inhibits expression or enzymatic activity of human aspartyl (asparaginyl) beta-hydroxylase (HAAH). The invention also features a method for diagnosing the growth of a malignant neoplasm (e.g., pancreatic cancer) in a mammal by contacting a tissue or bodily fluid from the mammal with an antibody which binds to a HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and/or detecting the antigen-antibody complex. | 04-15-2010 |
20100172832 | DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS - The invention features a method for diagnosing and inhibiting growth of a malignant neoplasm in a mammal by contacting a cell or a bodily fluid of the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide. Methods of immunization to generate an HAAH-specific immune response are also within the invention. | 07-08-2010 |
20110124016 | Diagnosis and Treatment of Malignant Neoplasms - The invention features a method of inhibiting tumor growth and/or tumor invasiveness in a mammal by administering to a mammal a compound (e.g., an antagonistic antibody) which inhibits expression or enzymatic activity of human aspartyl (asparaginyl) beta-hydroxylase (HAAH). The invention also features a method for diagnosing the growth of a malignant neoplasm (e.g., pancreatic cancer) in a mammal by contacting a tissue or bodily fluid from the mammal with an antibody which binds to a HAAH polypeptide under conditions sufficient to form an antigen-antibody complex and/or detecting the antigen-antibody complex. | 05-26-2011 |
20140271689 | Therapeutic Cancer Vaccine Targeted to HAAH (Aspartyl-[Asparaginyl]-beta-Hydroxylase) - The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-β-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer. | 09-18-2014 |
20140271691 | THERAPEUTIC CANCER VACCINE TARGETED TO HAAH (ASPARTYL-[ASPARAGINYL]-BETA-HYDROXYLASE) - The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-β-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer. | 09-18-2014 |
20140271812 | TREATMENT FOR CHEMOTHERAPY-INDUCED COGNITIVE IMPAIRMENT - The present invention provides methods and compositions for treating chemotherapy-induced cognitive impairment. One embodiment of the present invention is directed to a method of treating chemotherapy-induced cognitive impairment by administering to a patient in need at least one thiosemicarbazone compound. | 09-18-2014 |
20140287021 | TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - The present invention provides methods and compositions for treating chemotherapy induced peripheral neuropathy. One embodiment of the present invention is directed to a method of treating chemotherapy induced peripheral neuropathy by administering to a patient in need at least one thiosemicarbazone compound. | 09-25-2014 |
20140356930 | IMMUNE SYSTEM ENHANCING IMMUNOTHERAPY FOR THE TREATMENT OF CANCER - This application discloses immunoconjugates comprising antibodies against a particular target (such as cancer associated antigen or cancer specific antigen) that are conjugated with an immune enhancer, recruiter or solicitor. Also discloses are compositions and methods of using the inventive immunoconjugates to treat cancer. | 12-04-2014 |
20140363489 | TREATMENT OF EYE DISEASE - The present invention provides methods and compositions for treating retinal degeneration. One embodiment of the present invention is directed to a method of treating retinal degeneration by administering to a patient in need at least one thiosemicarbazone compound. | 12-11-2014 |